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Introduction: 
 Localization of parathyroid adenoma using 99mTc scintigraphy 
is the standard of care. However, of late, ultrasound has been 
employed to this end with increasing frequency.1, 2, 3 The employment 
of intra-operative PTH estimation (IOPTH) has further augmented the 
cure rate of hyperparathyroidism due to parathyroid adenomas.4 
While ultrasound is widely available, scintigraphy is available only in 
tertiary health-care centres.  
  
With this background, a prospective study was conducted in the 
department of endocrine surgery of a tertiary care hospital to analyse 
the efficacy of surgeon-performed ultrasound (SPUS) in comparison 
to that of 99mTc Sestamibi scintigraphy in the localization of 
parathyroid adenomas. 
Patients and methods: 
 Prospective data which were recorded over the past 5 years in 
this unit were retrospectively analysed. Consecutive patients with 
primary hyperparathyroidism were evaluated and managed. Serum 
levels of calcium (Ca), parathormone (PTH), alkaline phosphatase 
(AlP) and phosphate (PO4) were estimated. Levels of calcium in 24-
hr urine sample were estimated. Patients with hypercalcemia with 
elevation of serum calcium (S.Ca) levels more than 1 mg/dl above the 
upper limit of normal range and elevation of serum parathormone 
(S.iPTH) above five times the upper limit of normal range were 
included in the study. After confirmation of the diagnosis with 
biochemical tests, they were subjected to ultrasound and scintigraphy 
for localization of the parathyroid adenoma.  Patients in whom the 
  
above criteria were not met were excluded from the study. Those who 
were included in the study were classified into 2 groups. One group 
(Group 1) included patients who underwent both SPUS and 
scintigraphy, while the other group (Group 2) included patients who 
underwent SPUS alone. Patients were deemed to be cured of the 
disease if they remained symptom-free for a period of six months 
after surgery, with maintenance of eucalcemia in the above-said 
period.    
 
 
Results: 
A total number of 29 patients were included in the study.  The 
two groups were analysed with regards to mean age, S.Ca, S.iPTH, 
S.AlP 24-hr urinary calcium (Table 1).  
In group 1, the patients were aged between 31 and 55 yrs (40 +/- 
6.5). The mean serum calcium was 12.1 +/- 0.8 mg/dl (8.5 – 10.5). 
The mean S.iPTH was 389 +/- 45 pg/ml (15 – 65). The mean S.AlP 
  
was 298 +/- 76 IU/L. The mean 24-hr-urinary calcium was 280 +/- 
140 mg/24hrs. 
In group 2, the patients were aged between 35 and 60 yrs (44 +/- 
5.2).  ). The mean serum calcium was 12.3 +/- 0.7 mg/dl (8.5 – 10.5). 
The mean S.iPTH was 405 +/- 58 pg/ml (15 – 65). The mean S.AlP 
was 340 +/- 90 IU/L. The mean 24-hr-urinary calcium was 310 +/- 
160 mg/24hrs.  
There was no significant difference between the two groups 
with regards to these tests.  
The adenoma was localized to superior parathyroid in 6 patients 
and to the inferior parathyroid in 9 patients in group 1. In group 2, the 
adenoma was localized to the superior parathyroid in 6 patients and to 
the inferior parathyroid in 8 patients.  
There was no significant difference between the two groups 
with regards to the size of the adenoma, weight and post-operative 
levels of S.Ca (Table 2).  
2 patients in group 1 and 3 patients in group 2 developed 
Hungry bone syndrome. 
  
Discussion: 
 The success of parathyroid surgery depends upon the accuracy 
of localization of the adenoma. While ultrasound is widely available, 
scintigraphy is available only in tertiary health-care centres.  
 In the present study, there was no significant difference between 
SPUS and scintigraphy with regards to accuracy of identification of 
the adenoma. 
 Hence, on the basis of unequivocal biochemical diagnosis of 
parathyroid adenoma, SPUS is adequate for localization of adenoma 
and further management, including MIP. Scintigraphy is not a must 
for localization and non-availability of scintigraphy does not preclude 
MIP as an option for management of parathyroid adenoma.  
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